SI2451437T1 - Vodni pripravki, ki vsebujejo metionin - Google Patents

Vodni pripravki, ki vsebujejo metionin

Info

Publication number
SI2451437T1
SI2451437T1 SI201031388A SI201031388A SI2451437T1 SI 2451437 T1 SI2451437 T1 SI 2451437T1 SI 201031388 A SI201031388 A SI 201031388A SI 201031388 A SI201031388 A SI 201031388A SI 2451437 T1 SI2451437 T1 SI 2451437T1
Authority
SI
Slovenia
Prior art keywords
methionine
aqueous preparations
preparations
aqueous
Prior art date
Application number
SI201031388A
Other languages
English (en)
Inventor
Isabell Schoettle
Annika Hagendorf
Christiane Fuerst
Gerrit Hauck
Verena Siefke-Henzler
Walter Kamm
Julia Schnieders
Original Assignee
Sanofi-Aventis Deutschlad Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis Deutschlad Gmbh filed Critical Sanofi-Aventis Deutschlad Gmbh
Publication of SI2451437T1 publication Critical patent/SI2451437T1/sl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
SI201031388A 2009-07-06 2010-07-02 Vodni pripravki, ki vsebujejo metionin SI2451437T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102009031748 2009-07-06
DE102010013134 2010-03-27
PCT/EP2010/059436 WO2011003822A2 (de) 2009-07-06 2010-07-02 Insulinzubereitungen enthaltend methionin
EP10730443.8A EP2451437B1 (de) 2009-07-06 2010-07-02 Wässrige insulinzubereitungen enthaltend methionin

Publications (1)

Publication Number Publication Date
SI2451437T1 true SI2451437T1 (sl) 2017-03-31

Family

ID=43429596

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201031388A SI2451437T1 (sl) 2009-07-06 2010-07-02 Vodni pripravki, ki vsebujejo metionin

Country Status (32)

Country Link
US (1) US20120252724A1 (sl)
EP (2) EP2451437B1 (sl)
JP (1) JP5735960B2 (sl)
KR (2) KR101852328B1 (sl)
CN (4) CN105535943A (sl)
AR (1) AR077454A1 (sl)
AU (1) AU2010270325B2 (sl)
BR (1) BR112012000177B1 (sl)
CA (2) CA2980198C (sl)
CL (1) CL2012000026A1 (sl)
CO (1) CO6480996A2 (sl)
CY (1) CY1119582T1 (sl)
DK (1) DK2451437T3 (sl)
ES (1) ES2614161T3 (sl)
HR (1) HRP20170155T1 (sl)
HU (1) HUE030499T2 (sl)
IL (2) IL217327A (sl)
LT (1) LT2451437T (sl)
MA (1) MA33442B1 (sl)
MX (1) MX2012000304A (sl)
MY (1) MY159865A (sl)
NZ (1) NZ597757A (sl)
PH (1) PH12016500606A1 (sl)
PL (1) PL2451437T3 (sl)
PT (1) PT2451437T (sl)
RU (1) RU2540485C2 (sl)
SG (2) SG10201403840VA (sl)
SI (1) SI2451437T1 (sl)
TW (1) TWI520745B (sl)
UY (1) UY32764A (sl)
WO (1) WO2011003822A2 (sl)
ZA (1) ZA201200195B (sl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100111682A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
KR101820024B1 (ko) 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 glp-1 효능제의 병용물
US20120232002A1 (en) * 2009-07-06 2012-09-13 Sanofi-Aventis Deutschland Gmbh Slow-acting insulin preparations
HUE037735T2 (hu) 2009-11-13 2018-09-28 Sanofi Aventis Deutschland DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
ES2534191T3 (es) * 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
ES2566549T3 (es) * 2011-06-17 2016-04-13 Halozyme, Inc. Formulaciones estables de enzima degradante de hialuronano
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
AR094821A1 (es) * 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
US10441665B2 (en) 2012-07-25 2019-10-15 Hanmi Pharm. Co., Ltd. Liquid formulation of long acting insulinotropic peptide conjugate
EA201590882A1 (ru) * 2012-11-05 2015-09-30 Кейс Вестерн Ризерв Юниверсити Одноцепочечные аналоги инсулина длительного действия
NZ707160A (en) 2012-12-19 2016-08-26 Wockhardt Ltd A stable aqueous composition comprising human insulin or an analogue or derivative thereof
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US10130288B2 (en) 2013-03-14 2018-11-20 Cell and Molecular Tissue Engineering, LLC Coated sensors, and corresponding systems and methods
US10405961B2 (en) 2013-03-14 2019-09-10 Cell and Molecular Tissue Engineering, LLC Coated surgical mesh, and corresponding systems and methods
AR098168A1 (es) * 2013-10-25 2016-05-04 Sanofi Sa Formulación estable de insulina glulisina
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
US9895424B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US9839692B2 (en) 2014-01-09 2017-12-12 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP6970615B2 (ja) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング インスリングラルギン/リキシセナチド固定比処方
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療
CN117337299A (zh) * 2021-05-03 2024-01-02 印地安纳大学理事会 葡萄糖响应性胰岛素类似物葡萄糖传感器的分子设计

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6033474B2 (ja) * 1978-05-11 1985-08-02 藤沢薬品工業株式会社 新規なヒアルロニダ−ゼbmp−8231およびその製造法
DE3316363A1 (de) 1983-05-05 1984-11-08 Deutsche Babcock Anlagen Ag, 4200 Oberhausen Walzenrost fuer muellverbrennungsanlagen
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK257988D0 (da) 1988-05-11 1988-05-11 Novo Industri As Nye peptider
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
AU641631B2 (en) 1988-12-23 1993-09-30 Novo Nordisk A/S Human insulin analogues
NZ232375A (en) 1989-02-09 1992-04-28 Lilly Co Eli Insulin analogues modified at b29
DK155690D0 (da) 1990-06-28 1990-06-28 Novo Nordisk As Nye peptider
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
ATE413889T1 (de) * 1998-06-05 2008-11-15 Nutrinia Ltd Insulin angereichertes säuglingsnährpräparat
JP2007204498A (ja) * 1999-03-01 2007-08-16 Chugai Pharmaceut Co Ltd 長期安定化製剤
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
PT1491208E (pt) * 1999-10-04 2010-05-12 Novartis Vaccines & Diagnostic Composições farmacêuticas contendo polipéptido líquidas estabilizadas
AU2002248464A1 (en) * 2001-02-21 2002-09-12 Medtronic Minimed, Inc. Stabilized insulin formulations
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
PL377687A1 (pl) * 2001-10-18 2006-02-06 Bristol-Myers Squibb Company Środki naśladujące ludzki peptyd glukagonopodobny typu 1 i ich zastosowanie w leczeniu cukrzycy i stanów związanych z cukrzycą
EP1458408B1 (en) * 2001-12-21 2009-04-15 Novo Nordisk Health Care AG Liquid composition of factor vii polypeptides
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
TW200522976A (en) * 2003-09-19 2005-07-16 Novo Nordisk As Novel plasma protein affinity tags
US20080248999A1 (en) * 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
WO2007098479A2 (en) * 2006-02-21 2007-08-30 University Of Medicine And Dentistry Of New Jersey Localized insulin delivery for bone healing
TW200806317A (en) * 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
ES2402172T3 (es) * 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
SI2219607T1 (sl) * 2007-11-01 2012-09-28 Merck Serono Sa Tekoäśe formulacije lh
KR20100111682A (ko) * 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
KR101820024B1 (ko) * 2008-10-17 2018-01-18 사노피-아벤티스 도이칠란트 게엠베하 인슐린과 glp-1 효능제의 병용물
JP2009091363A (ja) * 2008-11-21 2009-04-30 Asahi Kasei Pharma Kk Pthの安定化水溶液注射剤
US20120232002A1 (en) * 2009-07-06 2012-09-13 Sanofi-Aventis Deutschland Gmbh Slow-acting insulin preparations
HUE037735T2 (hu) * 2009-11-13 2018-09-28 Sanofi Aventis Deutschland DesPro36exendin-4(1-39)-Lys6-NH2-t és metionint tartalmazó gyógyszerkészítmény
ES2534191T3 (es) * 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Composición farmacéutica que comprende un agonista de GLP-1, una insulina y metionina
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins

Also Published As

Publication number Publication date
UY32764A (es) 2011-01-31
EP2451437A2 (de) 2012-05-16
CN103690958A (zh) 2014-04-02
AU2010270325B2 (en) 2014-06-19
AR077454A1 (es) 2011-08-31
TW201113031A (en) 2011-04-16
PH12016500606A1 (en) 2016-11-28
WO2011003822A2 (de) 2011-01-13
CA2767251C (en) 2018-08-21
JP5735960B2 (ja) 2015-06-17
KR101852328B1 (ko) 2018-04-26
BR112012000177B1 (pt) 2021-06-01
IL217327A0 (en) 2012-02-29
BR112012000177A2 (pt) 2020-08-11
CA2980198A1 (en) 2011-01-13
US20120252724A1 (en) 2012-10-04
TWI520745B (zh) 2016-02-11
MY159865A (en) 2017-02-15
CN105535943A (zh) 2016-05-04
HUE030499T2 (hu) 2017-05-29
ES2614161T3 (es) 2017-05-29
EP3202394A1 (de) 2017-08-09
IL244941A (en) 2017-12-31
KR20120089442A (ko) 2012-08-10
SG10201403840VA (en) 2014-10-30
MA33442B1 (fr) 2012-07-03
WO2011003822A3 (de) 2011-08-25
CY1119582T1 (el) 2018-03-07
RU2540485C2 (ru) 2015-02-10
LT2451437T (lt) 2017-02-27
IL244941A0 (en) 2016-05-31
CN102596175A (zh) 2012-07-18
PL2451437T3 (pl) 2017-05-31
HRP20170155T1 (hr) 2017-03-24
CN107080836A (zh) 2017-08-22
PT2451437T (pt) 2017-01-17
MX2012000304A (es) 2012-01-27
DK2451437T3 (en) 2017-02-13
CL2012000026A1 (es) 2012-10-05
SG177567A1 (en) 2012-02-28
CA2980198C (en) 2019-04-30
CO6480996A2 (es) 2012-07-16
KR101853606B1 (ko) 2018-05-03
CA2767251A1 (en) 2011-01-13
KR20160036106A (ko) 2016-04-01
ZA201200195B (en) 2012-09-26
JP2012532178A (ja) 2012-12-13
NZ597757A (en) 2014-06-27
RU2012103901A (ru) 2013-08-20
EP2451437B1 (de) 2016-11-02
IL217327A (en) 2017-09-28
AU2010270325A1 (en) 2012-02-16

Similar Documents

Publication Publication Date Title
PL2451437T3 (pl) Wodne preparaty insuliny zawierające metioninę
HK1218558A1 (zh) 蛋白
PT2593094T (pt) Composição aquosa contendo bromexina
EP2346734A4 (en) ACTIVE WINGLET
EP2415450A4 (en) AQUEOUS HAIR DETERGENT
HK1164141A1 (en) External preparation for skin
EP2415452A4 (en) AQUEOUS HAIR DETERGENT
EP2433616A4 (en) COSMETIC PREPARATION
SI2630174T1 (sl) Vodni pripravki, ki imajo lastnosti mehkega otipa
HK1173965A1 (en) Aqueous patches containing diclofenac-sodium
EP2397246A4 (en) CONNECTED BODY
EP2520277A4 (en) AQUEOUS COSMETIC PREPARATION
EP2325250A4 (en) AQUEOUS EMULSION
ZA201109283B (en) Protein
GB2487167B (en) Cosmetic preparations
EP2515903A4 (en) COMPOUNDS, PREPARATION AND USES THEREOF
EP2398487A4 (en) Aqueous transfer buffer
EP2522327A4 (en) AQUEOUS COSMETIC PREPARATION
EP2520273A4 (en) COSMETIC PREPARATION
EP2641586A4 (en) AQUEOUS SHAMPOO
GB0711440D0 (en) Aqueous formulations
EP2392444A4 (en) AQUEOUS COATING AGENT
GB0902222D0 (en) Protein expression
GB0803235D0 (en) Aqueous formulations
AU2010905145A0 (en) Improving Aqueous Solubility